Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. Issue 3 (10th August 2017)

• Record Type: Journal Article
• Authors: Suda, Goki; Ito, Jun; Nagasaka, Atsushi; Yamamoto, Yoshiya; Furuya, Ken; Okamoto, Munenori; Terashita, Katsumi; Kobayashi, Tomoe; Tsunematsu, Izumi; Yoshida, Junichi; Meguro, Takashi; Ohara, Masatsugu; Kawagishi, Naoki; Kimura, Megumi; Umemura, Machiko; Izumi, Takaaki; Tsukuda, Yoko; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Sakamoto, Naoya
• Is Part Of: Hepatology research. Volume 48:Issue 3(2018)
• Page Start: E146
• Page End: E154
• Publication Date: 2017-08-10
• Subjects: add‐on -- fluvastatin -- hepatitis C virus -- simeprevir; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12938
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Background: The Japan Society of Hepatology guidelines indicate that hepatitis C virus (HCV) protease inhibitor combination therapy with simeprevir (SMV), pegylated‐interferon (Peg‐IFN), and ribavirin (RBV) is a therapeutic option for patients who fail to respond to a direct direct‐acting antiviral‐containing regimen. However, treatment outcomes have room for improvement. Fluvastatin (FLV) add‐on treatment in Peg‐IFN and RBV combination therapy for HCV‐infected patients significantly improved the sustained virologic response (SVR), but the add‐on effect of FLV on SMV combination therapy is not well understood. Methods: This was a prospective, randomized, multicenter study in which a total of 61 HCV genotype 1b‐infected patients were recruited and 60 eligible patients were randomly allocated to two groups that received 12 weeks of SMV/Peg‐IFN/RBV followed by 12 weeks of Peg‐IFN/RBV with or without 24 weeks of FLV. The SVR rate and adverse events were compared between the two groups. Results: Thirty‐one patients were allocated to the FLV add‐on group and 29 patients were allocated to the control group. Baseline clinical factors, including median age, baseline platelet count, alanine aminotransferase level, HCV RNA titer, Fibrosis‐4 index, and rate of IL28B minor genotype, were all similar between the two groups. The rapid virologic response, end‐of‐treatment response rates, SVR rates at 24 weeks after treatment, and safety profiles were also similar between the two groups. Conclusions: This prospective, randomized, multicenter study indicated that FLV had no add‐on effect when given with SMV/Peg‐IFN/RBV combination therapy for genotype 1b HCV‐infected patients.